Balaji AminesQ2 FY24

Balaji Amines Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,930.5P/E: 26.4Market Cap: ₹6.3K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • The company expects growth and increased prospects in FY 2024-25 as market conditions improve.
  • Ongoing projects (n-Butylamine, Methylamine, Dimethyl ether plants) are progressing on schedule, expected to add capacity.
  • Volume improvement is anticipated post current destocking phase, with return to pre-COVID price levels within two quarters.
  • Management is confident of margin improvement and better sales in the next two quarters.
  • Targets to increase export contribution to 25%-30% in 1-2 years from current 15%-17% to hedge imports.
  • Focus on new specialty products (NMM, NBPT, PVP K-30) first time in country, and solar power initiatives for sustainability.
  • Current headwinds in pharma and agrochemical segments expected to ease after this quarter.
  • Expect positive volume growth noted Y-o-Y despite recent revenue pressure due to realization impact.

See what Balaji Amines management said on margin guidance — free account, 30 seconds.

Fundraise plans

- The company is currently a zero-debt company on a standalone basis. - There is no explicit mention of any ongoing or planned fundraising through debt or equity in the transcript. - The company is focusing on strategic capex and new product projects for future growth. - The approach remains debt-free as emphasized by the management. - Expansion capex includes projects for n-Butylamine, Methylamine, Dimethyl Ether, and new specialty chemicals. - There is no indication of raising funds through equity either in this call. Summary: As of now, Balaji Amines Limited has not indicated any current or immediate plans for fundraising via debt or equity. The focus is on organic growth through internal accruals and strategic capex without incurring debt.

See what Balaji Amines management said on order book — free account, 30 seconds.

Capex plans

Yes
  • n-Butylamine plant expansion progressing rapidly; expected commission in Q4 FY 2023-24 (January-March 2024).
  • Methylamine project on track; likely commission in Q2 FY 2024-25.
  • Dimethyl ether (DME) plant initiated in Unit IV; civil works started; expected commission first half of FY 2024-25.
  • Proposal for new products at Unit IV:
  • - N-Methyl Morpholine (NMM) – 3,000 TPA
  • - N-(n-butyl) Thiophosphoric triamide (NBPT) – 2,500 TPA
  • - Pharmapure Povidone (PVP K-30) – 4,000 TPA (all first-time products in India)
  • Solar power plant projects for captive consumption at Unit IV (~1,600 KW, costing approx INR 7.5 crores) aimed at ESG compliance and reducing carbon footprint.
  • Initiated maintenance and debottlenecking in existing plants to improve product mix, realization, profitability, and capacity utilization.
  • Proposal to acquire additional land for future expansions, including Balaji Specialty Chemicals Unit II with environmental clearance process underway.

Track Balaji Amines — get its next earnings analysis in your feed

How does Balaji Amines rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisBalaji Amines
Rev 3Mar 1

How does Balaji Amines rank in Chemicals & Petrochemicals?

Compare Balaji Amines against every Chemicals & Petrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →